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about 34% of that in the adrenals and all other organs were <12% of the adrenal uptake at 60 minutes post injection. Metabolite analysis showed 13% unchanged [ 18 F] FAMTO in blood at 10 minutes post administration and rapid urinary excretion. In vitro assays in human blood showed a free fraction of 37.5%.
Conclusions
[ 18 F]FAMTO, a new 18 F-labelled analogue of metomidate, was successfully synthesised. In vitro and in vivo characterization demonstrated high selectivity towards aldosterone-producing enzymes (CYP11B1 and CYP11B2), supporting the potential of this radiotracer for human investigation.
A C C E P T E D M A N U S C R I P T
Introduction
The most common secondary cause of hypertension is primary aldosteronism (PA), which is reported in approximately 6-15% of all hypertensive patients. By the year 2025, PA is expected to directly impact one in four people with hypertension globally [1] [2] [3] [4] [5] [6] [7] . PA is characterized by an excess secretion of aldosterone, steroid hormone with mineralocorticoid activity produced by the zona glomerulosa of the adrenal cortex where aldosterone synthase (CYP11B2) enzymes play an essential role in aldosterone production [3, 8, 9] . Aldosterone increases sodium reabsorption and potassium excretion in the renal distal tubules and collecting ducts of nephrons, influencing water retention and blood pressure [3] . Therefore, pathological conditions showing an overproduction of aldosterone frequently lead to hypertension and hypokalaemia resulting in detrimental effects to an individual's cardiovascular system [1] . Over 90% of all PA patients have a sporadic form [10] . The two most common subtypes of sporadic PA are unilateral aldosterone-producing adenomas (UAPA, 40%) or bilateral adrenal hyperplasia (BAH, 60%) [5, 11] . Correctly differentiating between the unique features of UAPA and BAH is crucial in identifying an appropriate intervention. UAPA is curable through surgical removal of the diseased adrenal whilst BAH is treated pharmacologically with mineralocorticoid receptor antagonists (e.g. spironolactone) [12] . The most significant obstacle for decision makers is the need to distinguish UAPA from other causes of PA such as BAH or non-functioning adrenal adenoma (incidentalomas) [13] . Invasive bilateral adrenal vein sampling (AVS) is the current gold-standard diagnostic procedure adopted, with cannulation success rates varying from 8% to 95% [10, [14] [15] [16] .
Computed tomography (CT) and magnetic resonance imaging (MRI) have been used for noninvasive lateralisation of aldosterone hypersecretion. These show low diagnostic accuracy due to
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A C C E P T E D M A N U S C R I P T 5 suboptimal spatial resolution and sensitivity to detect small UAPA (<1 cm) [14, [17] [18] [19] [20] . Positron emission tomography (PET) is considered an accurate and non-invasive alternative to AVS in the management of patients with PA and adrenal adenoma [21] .
Methyl and ethyl esters of 1-[(1R)-1-phenylethyl]-1H-imidazole-5-carboxylic acid, such as (R)-metomidate (MTO, Fig. 1 ) and (R)-etomidate (ETO), are a class of compounds that interact with the mitochondrial cytochrome P-450 enzymes (11β-hydroxylase (CYP11B1) and CYP11B2) in the adrenal cortex (IC 50 for CYP11B1 = 0.24±0.05 nM (MTO) and 0.5±0.2 nM (ETO), IC 50 for CYP11B2 = 0.59±0.64 nM (MTO) and 1.7±0.9 nM (ETO)) [22] [23] [24] . MTO and ETO have been used as template to develop PET radiolabelled radiotracers using β + -emitting radionuclides such as 11 C and 18 F [21, 25, 26] .
Bergström et al. have developed [ 11 C]MTO ( Fig. 1 ) by radiolabelling the methyl ester group with 11 C. [ 11 C]MTO possesses high specific binding to adrenal enzymes in vitro and in nonhuman primate studies [25, 27, 28] . Blocking experiments using ETO (10 μM) confirmed the specific uptake of [ 11 C]MTO to pig adrenal sections [25] . In humans [ 11 C]MTO showed high uptake in adrenal glands (SUV ratio of adrenal gland/liver ratio 1.5±0.7, 15-45 min) and high standardised uptake values (SUV) in aldosterone-hypersecreting adenomas [25, 27, [29] [30] [31] .
Metabolite studies of [ 11 C]MTO in humans revealed that unchanged [ 11 C]MTO accounted for 40% and 28% of total blood-borne radioactivity at 20 min and 40 min post injection, with two polar metabolites present in the plasma [30] . Although [ 11 C]MTO has good imaging properties for visualization of UAPA, [21] novel radiotracers with increased adrenal-to-liver ratio (large liver uptake hampers the assessment of the right adrenal) and a longer half life radionuclide (e.g. 18 F) are needed for a more widespread adoption of this diagnostic approach.
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6 An increased adrenal-to-liver PET signal was achieved by adding a halogen atom (e.g. chlorine or bromine) in the para-position of MTO's benzene group such as chlorine ([ 11 C]ClMTO, Fig. 1 ) and bromine ([ 11 C]BrMTO, Fig. 1 ). In rats [ 11 C]MTO gives an adrenal-to-liver ratio of 3.8 at 30 min post injection, increasing to 4.4 and 7.2 using [ 11 C]ClMTO and [ 11 C]BrMTO, respectively [32] . [ 11 C]MTO is not used in a widespread manner, partly because of its short half-life that limits its use to PET centres with on-site cyclotrons. A MTO analogue with a longer fluorine-18
half-life would enable the examination of more patients per tracer production, and its distribution to PET-centres without on-site cyclotrons. [34] . [ 18 F]FETO was produced using an automated one-step protocol within 70 min (total synthesis time) with a non-isolated radiochemical yield (RCY) of 20±3% [35] . Regional organ distribution of [ 18 F]FETO in rat revealed an adrenal-to-liver ratio of 14.48 at 60 minutes post injection [36] . Metabolite analysis indicated that [ 18 F]FETO is degraded to 2-[ 18 F]fluoroethanol in vitro and in vivo [37] . In humans, [ 18 F]FETO is rapidly metabolised in the first 10 minutes (91% intact [ 18 F]FETO after 2 minutes; 24% after 10 min, 11% after 20 min and 3.7% after 90 min) [37] . [ 11 C]MTO and [ 18 F]FETO showed rapid metabolism in vivo corresponding to de-esterification to the non-radioactive and inactive carboxylic acid derivative (IC 50 =0.12 mM) [34, 38] and radioactive metabolites, such as [30, 36, 37] .
A para-fluorinated aromatic (R)-MTO derivative (FAMTO, Fig. 1 ) has comparable affinity for adrenal enzymes (K i = 7.3 nM measured using [ 131 I]IMTO ) as MTO (K i = 4.02 ± 1.87 nM) in rat adrenal membranes [39] . We therefore developed a radiosynthetic strategy to produce a 18 Fradiolabelled analogue of MTO ([ 18 F]FAMTO) in order to evaluate it as a potential radiotracer for aldosterone-producing adenomas. (Cu(OTf) 2 (py) 4 , 3.6 mg, 5 µmol) were added in a vial. DMF was added to achieve a final volume of 500 µL (see Table 2 ). Radiofluorination was conducted at 118 °C for 20 min, cooled to room temperature, and diluted with H 2 O.
Materials & Methods

General Consideration
Low base procedure: Aqueous [ 18 F]fluoride ion (100-1000 MBq) was loaded onto a QMA cartridge, the cartridge was flushed with air and the 18 F elution was performed using 2 mL of K 222 (1.5 µmol) and K 2 CO 3 (0.87 µmol) in MeCN: H 2 O (80:20). Azeotropic drying was performed by addition of MeCN (2 x 1 mL) and heating at 90 °C under a stream of N 2 . To the dried mixture DMF (500, 300, 200, and 100 µL), 2 (6.3 mg, 18 µmol) and Cu(OTf) 2 (py) 4 (3.6 mg, 5 µmol) were added (see Table 2 ). Radiofluorination was conducted at 118 °C for 20 min under air, cooled to room temperature, and diluted with H 2 O.
Purification and Analysis of [ 18 F]FAMTO
The crude mixture was purified by semi-preparative HPLC (see Appendix A). The purified [ 18 F]FAMTO was subsequently diluted with 40 mL of PBS, the solution loaded onto a Sep-Pak tC18 Plus Long SPE Cartridge 900 mg, 37-55 µm (cat. no. WAT036800, Waters) and eluted with ethanol (2 mL). Ten fractions (0.2 mL) were collected and radioactivity determined.
Fractions with highest radioactivity were combined and formulated with saline. The formulated solution (4-6 mL of 10% ethanol in saline) containing 1-10 MBq of [ 18 F]FAMTO was used for in vitro and in vivo experiments. Analytical reverse-phase HPLC (see Appendix A) was used to determine the molar activity, radiochemical and chemical purity. Identification of the radioactive products was confirmed by co-elution of added non-radioactive compounds.
Determination of chiral conformation and enantiomeric excess of 2,4 and [ 18 F]FAMTO
Circular dichroism (CD) spectra of (R)-ETO (enantiomeric excess (e.e.) > 99%, Sigma (Table S2 ). Commercial (R)-ETO (e.e. > 99%) and (S)-8 (e.e. > 97%) were used as control.
Determination of RCY and molar activity of [ 18 F]FAMTO
The entire quenched reaction mixture was used to determine non-isolated and isolated RCY.
All RCYs are reported as decay corrected values [40] . Non-isolated RCYs were determined by integrating the area under the curve in the preparative radio-HPLC chromatogram or iTLC. The molar activities (GBq/µmol) were calculated by dividing the radioactivity of [ 18 F]FAMTO by the amount of the unlabeled FAMTO determined from the peak area in the UV-HPLC chromatograms (λ= 254 nm, common wavelength for identifying metomidate derivative compounds such as etomidate and iodometomidate [25, 38] , fig. S1 ). FAMTO concentrations were determined from a UV-absorbance calibration curve (see Appendix A).
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Pig Organ Tissues
Pig tissues were purchased from Seralab, UK. Adrenal glands, kidneys, and liver were collected from an healthy animal (female, 9 months old). Tissues were delivered at 4 °C in Dulbecco's media. Once collected, tissues were cut in small and medium pieces. Pieces were snap frozen in an isopentane bath cooled to -30 °C and stored at -80 °C.
Autoradiography
Frozen sections (20 μm) of pig adrenal glands, kidneys, and liver were prepared in a Cryostat and put on superfrost glass slides. At the start of the experiment, the slides warmed to room temperature and preincubated for 10 min in TRIS buffer (50 mM, pH 7.4). Slides were then transferred to containers containing 1 nM of [ 18 F]FAMTO in 40 mL of TRIS buffer (50 mM, pH 7.4). In a duplicate set of containers, 1 μM of MTO was added to block specific binding. After incubation for 30 minutes (the slides were washed 2×3 min in fresh 50 mM TRIS buffer, pH 7.4). The slides were dried and then exposed to phosphor imaging plates (BAS-IP TR 2040, GE Healthcare, UK) for 30 minutes and scanned in a Typhoon 8600 phosphorimager (GE Healthcare, UK). Images (Fig. 2 ) were analysed using OptiQuant 5.0 software (PerkinElmer, UK).
Animal Studies
Biodistribution and metabolite studies were carried out in adult male Sprague-Dawley rats 3A and Table S1 ). Data are expressed as mean ± standard error (SE) from three independent replicates, unless otherwise indicated. Statistical analysis of %ID/g in the biodistribution study was performed with IBM SPSS Statistics (version 24). Student t-tests were used to determine statistical significance with P < 0.05 considered significant.
Analysis of Radiolabelled Metabolites in Rats
Blood and urine samples were collected at 10, 30, and 60 minutes post injection to measure the amounts of unchanged tracer and radioactive metabolites. Blood was centrifuged at 6000 rpm for 5 min, the supernatant was treated with MeCN (1:1) and centrifuged to precipitate plasma proteins. Plasma supernatant and urine samples were then injected into an HPLC semipreparative column (see Appendix A), and the eluate collected in 1.5 mL test tubes and gamma-counted.
Two metabolites (t R = 3 and 21 minutes) and [ 18 F]FAMTO were observed in the plasma (Fig. 4 ).
One metabolite (t R = 3 minutes) was observed in the urine (Fig. S2 ). 2.5 μL aliquots of radioactivity eluting at t R = 3 minutes and compound 12 (Scheme 1) were analysed by TLC and analysed using OptiQuant 5.0 software (PerkinElmer, UK).
Stability Studies in Plasma
Human blood (1 mL) was incubated with 0.7-1 MBq (200 µL) [ 18 F]FAMTO at room temperature for 10 and 20 minutes. After incubation, plasma was separated by centrifugation (5 min, 4000×g) and the proteins were precipitated by the addition of an equal volume of MeCN.
The tubes were centrifuged for 5 min at 4000×g. The supernatant was then injected onto the HPLC (HPLC method 1) and serial 1.5 mL HPLC fractions were collected and gamma-counted.
[ 18 F]FAMTO (0.7-1 MBq, 200 µL) incubated in PBS (1 mL) was used as control.
Plasma Protein Binding
The plasma protein binding of [ 18 F]FAMTO was measured in the plasma of blood samples.
Plasma was prepared from fresh human blood by centrifugation ( 
Results
Chemistry
Aryl sulfonium salt 1 (Scheme 1) was synthesised following the procedure reported by Sander et al. [41] . The thioether 5 reacted with diaryliodonium triflate under copper(II) catalysis (125 °C, 1 h) giving 1 in 53% yield. Pinacol boronate ester 2 was prepared by the following procedure adapted from the literature [42] . The para-bromo MTO derivative (6) reacted with bis(pinacolato)diboron in the presence of potassium acetate and Pd-catalyst to form 2 with a yield of 76±10% (n=3).
Scheme 1 shows the route used to synthesize 3-6 via Mitsunobu reaction that involves the use of both an oxidising agent such as di-tert-butyl azodicarboxylate (DtBad) and a reducing agent such as triphenylphosphine (PPh 3 ) under mild conditions. Yields between 40-60% were obtained.
Radiosynthesis of [ 18 F]FAMTO
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14 Two 18 F-labeling strategies were selected to produce [ 18 F]FAMTO, the first via an aryl sulfonium salt (1, Scheme 1) and the second via an aryl boronic precursor (2) .
The strategy of labeling sulfonium salts with 18 F fluoride ion has been reported to be a direct, straightforward nucleophilic substitution [41] . Following the optimised procedure developed by Table 2 ).
Neumaier and coworkers have reported an efficient protocol to increase the RCY of coppermediated aromatic radiofluorination using a "low amount of base" strategy [43] . Indeed using small amount of K 222 /K 2 CO 3 in DMF obtained by aliquoting the dried residue of [ 18 F]fluoride
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15 ion/K 222 /K 2 CO 3 (K 222 = 10 μmol and K 2 CO 3 = 6 μmol), a selective 18 F-incorporation was observed affording [ 18 F]FAMTO with a non-isolated RCY of 17% (entry 2, Table 2 ). As the "low base" approach gave promising results, we further reduced the amount of K 222 and K 2 CO 3 present in the reaction solution. Decreasing 2-and 4-times the amount of K 222 and K 2 CO 3 , [ 18 F]FAMTO was produced with a RCY between 16-23% (entries 3-4, Table 2 ).
Subsequent experiments were performed using the same amount of K 2 CO 3 and K 222 for [25] . Blocking studies revealed a high specific binding in the liver and kidney, organs known to be rich in cytochrome P450 enzymes.
Ex Vivo Biodistribution, metabolite analysis and in vivo PET Imaging Studies in Rats
Ex vivo biodistribution data ( Fig. 3A and Table S1 ), performed in healthy Sprague-Dawley rats, was used to assess the adrenal uptake as well as the adrenal-to-organ ratio. [ 18 F]FAMTO showed high liver uptake in the first 10 minutes (%ID/g = 3.61 ± 1.53) followed by a slight decrease at 30 min (%ID/g = 2.16 ± 1.53) and 60 min (%ID/g = 1.68 ± 0.18). Adrenal uptake increased slowly during the first 30 minutes up to %ID/g = 6.2 ± 0.46, followed by a slow decrease up to %ID/g = 4.92 ± 0.70 at 60 minutes. Adrenal-to-liver ratio increased from 0.66 at 10 minutes to 2.8 at 30 minutes postinjection ( Fig. 3A and Table S1 ).
Rats that received ETO (1 mg/kg) 10 minutes prior to injection of [ 18 F]FAMTO showed a significant decrease in liver uptake (66%, p = 0.005, see Table S1 ) and a moderate decrease in the adrenal glands (39%, p = 0.03). Pre-treatment with ETO increased the ratio of %ID/g in adrenal to liver by 38% (p = 0.12) leading to an enhanced adrenal-to-liver PET signal compared to the non-pretreatment group. An in vivo PET image of the adrenal uptake of [ 18 F]FAMTO after pre-treatment with ETO (1 mg/kg) is shown in Fig. 3B and S4 .
Plasma metabolite analysis revealed 13%, 8% and 2% of unchanged [ 18 F]FAMTO at 10, 30 and 60 minutes post-injection, respectively. Two hydrophilic metabolites at retention times 3 and 21 minutes were observed (Fig. 4) . The metabolite eluting at 3 minutes has been identified as the free acid [ 18 F]12
A C C E P T E D M A N U S C R I P T 17 ( Fig. S3 ). Urine metabolite analysis revealed only one metabolite in solution corresponding to [ 18 F]12 ( Fig. S2 ).
Stability Studies in Human Blood And Plasma Free Fraction
Plasma-derived metabolites can cause a non-specific signal that reduces the specificity and quality of PET imaging endpoints. Metabolite studies of [ 11 C]MTO or [ 18 F]FETO in humans revealed that unchanged radiotracer accounted for 40% and 11% of total blood-borne radioactivity at 20 min post injection, respectively and, considering the rapid in vivo metabolism of both radiotracers [30, 37] , we decided to perform [ 18 F]FAMTO metabolite studies over a similar (20 minutes) timeframe for comparison. No degradation of [ 18 F]FAMTO was observed after incubation in human blood for 20 minutes. The plasma free fraction of [ 18 F]FAMTO was determined to be 37.55 ± 5.78% (mean ± SD, n=5) by ultrafiltration.
Discussion
The development of the novel 18 F radiotracer targeting adrenal gland enzymes represents a valuable advancement to the field of PA PET imaging. Our PET radiotracer development approach started from the structure-activity relationship analysis of MTO (K i = 4.02 ± 1.87 nM), a potent inhibitor of CYP11B1 and CYP11B2 adrenal gland enzymes, and its derivatives bearing a halogen atom on the benzene ring (e.g. Br, I and F). Initial investigations, focused on using previously recognised strategies to incorporate fluorine-18
into aromatic rings in a one-step reaction using synthetically accessible precursors such as aryl sulfonium salt 1 or an aryl boronic precursor 2 to obtain the R-enantiomer of [ 18 F]FAMTO. The Rconfiguration of MTO (IC 50 = 3.69 ± 1.92 nM) is a 130 times more potent an inhibitor than its Senantiomer (IC 50 = 492 ± 281 nM) [34] .
Using the aryl sulfonium strategy, a benzylic 1H-imidazole derivative, ETO fragment, has been radiolabelled by Sander et al. in 31% RCY [41] . Applying the same conditions to 1, the production of In vivo studies confirmed the high specificity of [ 18 F]FAMTO uptake in adrenal glands showing a ratio of adrenal-liver uptake of 2.81 at 30 minutes post injection, which is similar to the adrenal gland-to-liver ratio of [ 11 C]MTO in rats (3.8 at 30 min) [46] . This ratio would be expected to be elevated in the presence of UAPA due to an overexpression of adrenal enzymes [8, 47] . Fig. 4, Fig. S2 and S3 ). In analogy to the carboxylic acid derivative of MTO, we anticipate that compound 12 would also have negligible affinity for adrenal gland enzymes [34] .Low metabolic stability of MTO and FETO has been observed in vitro and in vivo [30, 37] . However, in humans [ 18 
CONCLUSION
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